-
Press ReleaseNovartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
-
Press ReleaseNovartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
-
Story
A scientist from the start – Q&A with NIBR President Fiona Marshall -
Story
In neuroscience, “an inflection point in knowledge and technology” -
Press ReleaseNovartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
-
Story
When it comes to cancer, there’s power in a good partner -
Story
Stopping this coronavirus – and the next one -
Story
Solving the puzzle of immunotherapy -
Story
Toward regrowing cartilage -
Story
The search for new options for patients with lung cancer -
Story
Discover how inflammation could fan the flames of cancer -
Story
Take a visual tour of medicines that target RNA